🇺🇸 FDA

Intelligence Platform

Patents

Browse 454 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10188648

Solid state forms of selexipag

TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Tue Jan 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10130621

Analogs of pridopidine, their preparation and use

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Nov 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10035802

Solid state forms of ibrutinib

Teva Pharmaceuticals USA, Inc. · Granted Tue Jul 31 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10034866

Inhalable medicament comprising tiotropium

Teva Branded Pharmaceutical Products R&D, Inc. · Granted Tue Jul 31 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9980904

Dry powder formulation

Teva Branded Pharmaceutical Products R&D, Inc. · Granted Tue May 29 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 24 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9963515

Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B

TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Tue May 08 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 03 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9951017

S1P3 antagonists

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Apr 24 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9896502

Antagonist antibodies directed against calcitonin gene-related peptide and methods using s

TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Tue Feb 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9890210

Antagonist antibodies directed against calcitonin gene-related peptide

TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Tue Feb 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9890211

Antagonist antibodies directed against calcitonin gene-related peptide

TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Tue Feb 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9884908

Methods for treating headache using antagonist antibodies directed against calcitonin gene

TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Tue Feb 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9884907

Methods for treating headache using antagonist antibodies directed against calcitonin gene

TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Tue Feb 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9814706

Hydrobromide salt of pridopidine

TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Tue Nov 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9796673

L-tartrate salt of pridopidine

TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Tue Oct 24 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9763904

Position-specific asymmetric deuterium enriched catecholamine derivatives and medicaments

TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Tue Sep 19 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9763993

Process for manufacturing glatiramer acetate product

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Sep 19 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9707295

Inhalable medicament

Teva Branded Pharmaceutical Products R&D, Inc. · Granted Tue Jul 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9702007

Genetic markers predictive of response to glatiramer acetate

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Jul 11 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9687522

Methods of treating a subject afflicted with an autoimmune disease using predictive biomar

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Jun 27 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 22 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9682033

Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole

TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Tue Jun 20 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 15 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9662322

Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients wit

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue May 30 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 25 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9655969

Inhalable medicament comprising tiotropium

Teva Branded Pharmaceutical Products R&D, Inc. · Granted Tue May 23 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 18 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9636334

Combination of lenalidomide and polypeptide construct, and uses thereof

TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Tue May 02 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 27 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9625473

Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Apr 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted